19 Osteogenesis Imperfecta Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in Tucson

NCT00736749Recruiting

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep tr...

Tucson, AZ5,000 participantsChildren's Oncology Group

View Study Details

NCT05564390Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical tria...

Tucson, AZPHASE22,000 participantsNational Cancer Institute (NCI)

View Study Details

NCT07358078Recruiting

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine cli...

Tucson, AZ2,000 participantsAlnylam Pharmaceuticals

View Study Details

NCT06556602Recruiting

Methadone Patient Access to Collaborative Treatment

The trial of Methadone Patient Access to Collaborative Treatment (MPACT) will establish the impact of the intervention on patient outcomes of methadone treatment retention and in treatment overdose. ...

Tucson, AZNA1,080 participantsUniversity of Arizona

View Study Details

NCT05862272Recruiting

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatm...

Tucson, AZPHASE31,000 participantsSumitomo Pharma Switzerland GmbH

View Study Details

NCT04692493Recruiting

RA-PRO PRAGMATIC TRIAL

The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medicatio...

Tucson, AZPHASE3924 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06852222Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukem...

Tucson, AZPHASE3600 participantsJanssen Research & Development, LLC

View Study Details

NCT05865301Recruiting

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozog...

Tucson, AZ500 participantsStanford University

View Study Details

NCT05208047Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two...

Tucson, AZPHASE3482 participantsCogent Biosciences, Inc.

View Study Details

NCT06022939Recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versu...

Tucson, AZPHASE3338 participantsSWOG Cancer Research Network

View Study Details

NCT05554406Recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with...

Tucson, AZPHASE2335 participantsNational Cancer Institute (NCI)

View Study Details

NCT07276581Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163....

Tucson, AZPHASE2320 participantsAstraZeneca

View Study Details

NCT07409103Recruiting

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enro...

Tucson, AZPHASE2180 participantsElevara Medicines Limited

View Study Details

NCT06317649Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit...

Tucson, AZPHASE2147 participantsNational Cancer Institute (NCI)

View Study Details

NCT07547215Recruiting

Post-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion

The purpose of this study is to evaluate the real-world performance, safety and efficacy of the TRAQ System....

Tucson, AZ100 participantsPainTEQ, LLC

View Study Details

NCT06672146Recruiting

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed...

Tucson, AZPHASE293 participantsNational Cancer Institute (NCI)

View Study Details

NCT07086976Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approx...

Tucson, AZPHASE390 participantsSanofi

View Study Details

NCT06991114Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of ...

Tucson, AZPHASE290 participantsArtiva Biotherapeutics, Inc.

View Study Details

NCT07385638Recruiting

Olorofim in Early Coccidioidal Meningitis

This research study is being conducted to learn more about the use of olorofim in Coccidioidal (Cocci) meningitis, a rare but serious fungal infection that affects the brain and spinal cord. The study...

Tucson, AZPHASE212 participantsFariba Donovan

View Study Details

About Osteogenesis Imperfecta Clinical Trials in Tucson

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 19 osteogenesis imperfecta clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 15,291 participants. Research is being sponsored by Children's Oncology Group, National Cancer Institute (NCI), Alnylam Pharmaceuticals and 13 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Tucson — FAQ

Are there osteogenesis imperfecta clinical trials in Tucson?

Yes, there are 19 osteogenesis imperfecta clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 19 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated October 20, 2026 from ClinicalTrials.gov